Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer.
Whitney L HensingLorenzo GerratanaKatherine K CliftonArielle J MedfordMarko VelimirovicAmi N ShahPaolo D'AmicoGiancarlo FelicielloQiang ZhangCharles S DaiElyssa N DenaultNusayba A BagegniMateusz OpyrchalFoluso O AdemuyiwaRon BoseAmir BehdadCynthia X MaAditya BardiaMassimo CristofanilliAndrew A DavisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.